Phase Ib/II study of lacnotuzumab (MCS110) combined with spartalizumab (PDR001) in patients (pts) with advanced tumors.

被引：26

作者：

Calvo, Aitana

Joensuu, Heikki

Sebastian, Martin

Naing, Aung

Bang, Yung-Jue

Martin, Miguel

Roda, Desamparados

Hodi, F. Stephen

Veloso, Artur

Mataraza, Jennifer

Baneyx, Guillaume

Guerreiro, Nelson

Liao, Serena

Rabault, Bertrand

Fjaellskog, Marie-Louise

Cervantes, Andres

机构：

[1] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[2] Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland

[3] Univ Klinikum Frankfurt, Frankfurt, Germany

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Seoul, South Korea

[6] Inst Invest Sanit INCLIVA, Valenica, Spain

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Novartis Inst BioMed Res, Cambridge, MA USA

[9] Novartis Pharma AG, Basel, Switzerland

[10] Novartis Inst BioMed Res, Basel, Switzerland

来源：

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.3014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3014

引用

页数：1